Objectives There is a need for research into designing effective pharmaceutical systems for delivering therapeutic drugs to the posterior of the eye for glaucoma-related pathology, macular degeneration, diabetic retinopathy, macular oedema, retinitis and choroiditis. Conventionally, eye drops have been extensively utilised for topical drug delivery to the anterior segment of the eye, but are less effective for delivery of therapeutics to the back of the eye due to significant barriers hampering drug penetration into the target intraocular tissue. This review explores some of the current and novel delivery systems employed to deliver therapeutics to the back of the eye such as those using liposomes, ocular implants, in situ gels, and nanoparticles, and how they can overcome some of these limitations. Key findings Issues such as blinking, precorneal fluid drainage, tear dilution and turnover, conjunctiva and nasal drug absorption, the corneal epithelium, vitreous drug clearance, and the blood-ocular barriers are reviewed and discussed. Summary Further studies are needed to address their shortcomings such as drug compatibility and stability, economic viability and patient compliance.
Introduction
Ocular conditions such as diabetic retinopathy, macular oedema, chorioretinitis and macular degeneration are relatively common conditions that require ongoing long-term treatment. The use of topic drug delivery using eye drops has long been a mainstay pharmaceutical treatment for these conditions. However, the use of eye drops has its limitations and drawbacks as the drug in its vehicle has to penetrate the innate static and dynamic barriers in the eye to display therapeutic effects. [1] Therefore, over the last few decades, new drug delivery systems have been developed to overcome these barriers. The development of new drug delivery systems may be particularly beneficial in treating specific conditions where established methods may be lacking. [2] The purpose of this review article is to examine the key barriers limiting topical and systemic drug delivery and, more importantly, how the use of some novel drug delivery methods ( Figure 1 ) may assist in overcoming these issues.
Barriers impeding posterior segment ocular drug delivery
Compared to diseases affecting other body tissues, diseases of the eye can be treated with a wider range of drug delivery systems. For example, diseases such as glaucoma-related pathology, uveitis, macular degeneration and retinopathy have been treated using a range of delivery vehicles ranging from eye drops to injections and ocular implants. Traditionally, eye drops have been employed for topical drug delivery to the anterior segment of the eye but less so for the posterior segment due to the significant physiological, anatomical and dynamic ocular barriers impeding drug penetration into the target intraocular region.
Primary physiological barriers
Perhaps some of the most significant barriers (Table 1) to topical ocular drug delivery are the primary physiological barriers of the eye including the blinking mechanism, the hydrophilic tear film of the eye, tear dilution and turnover, the limited conjunctival sac volume of 10 ll, and nasolacrimal drainage. [3] For example, one of the principal factors contributing to low transcorneal absorption is fluid drainage of up to 80-90% of the drug into the nasolacrimal duct. This is due primarily to the limited conjunctival sac volume of 10 ll. This drainage rate has been found to be increased by a few factors including a higher instilled volume, a decreased viscosity, a pH different from 7.0 to 7.7, as well as non-isotonic vehicles and certain drugs. [3, 4] For example, based on a pharmacokinetic model, Avtar and Tandon [5] showed that the aqueous humour concentration (and thus, transcorneal penetration) of a drug can be increased if the drug clearance rate and distribution volume in the anterior chamber is decreased for both lipophilic and hydrophilic molecules. Additionally, blinking upon administration of eyedrops aids in this fluid drainage as blinking forces the fluid vehicle from the conjunctival sac and into the nose by compressing the lacrimal duct. [6] Besides drainage, the turnover of the tear film also poses as a significant barrier with drainage of tears occurring at 1 ll/min (or about 16% of the tear film per minute). [7] This second mechanism of clearance results in a slow steady loss of precorneal drug concentration after the initial rapid clearance through the nasolacrimal duct. As a result of these many factors, the contact time of therapeutics with the absorptive membrane is significantly lowered and is the primary reason why the instilled drug is typically washed away in 15-40 s. Consequently, <5% of drug dose typically reaches the intended intraocular vitreous body. [8, 9] Additionally, there is evidence that changes to other delivery factors have minimal effects on ocular penetration such as increased drop size (due to the limited conjunctival volume) [8] or increased viscosity (which may increase residence time but decrease corneal permeation). [10, 11] Conjunctiva and nasal absorption of drug In addition to the primary physiological barriers discussed above, another major barrier that acts to decrease drug concentration at the site of the absorptive membrane is the systemic absorption of drug through the dense and compact vascularisation of blood and lymphatic capillaries in the conjunctiva and nasal cavity. [12] Depending on the therapeutic drug, this mechanism can increase systemic adverse effects ranging from hypotension and bradycardia in timolol to palpitations and headaches in adrenaline eye drops, especially in paediatric and elderly cohorts. [13, 14] In addition to conjunctival and lacrimal drainage into the nasal cavity, the drug absorption into the conjunctiva, lacrimal ducts, and nasal cavity also accounts for a significant loss of precorneal drug bioavailability, with absorption from the nasal mucosa contributing to the most drug absorption. [15] This is particularly a problem considering the limited permeability of the cornea. For example, the surface area of the conjunctiva is 17 times greater than that of the cornea [16] and at least twice as permeable, especially for polar macromolecules. [17] Consequently, this reduced precorneal drug bioavailability necessitates higher drug concentrations and more frequent administration, which in turn can increase the risk of adverse effects.
However, as will be discussed, formulation changes can be adapted to decrease conjunctiva absorption. For example, increasing the viscosity of the vehicle (to decrease conjunctiva absorption) as well as co-administering drugs with phenylephrine (to vasoconstrict conjunctiva and nasal capillaries) has been found to improve corneal contact time and bioavailability. [18] Corneal epithelium barrier
The cornea is one of the most significant biological and mechanical barriers to posterior ocular drug delivery. The cornea is a transparent tissue at the front of the eye consisting of five layers: the epithelial layer, Bowman's membrane, stroma, Descemet's membrane and endothelial layer. Of these layers, the epithelium is the major barrier for transcorneal permeation, especially for nanoparticles and larger molecular weight drugs. [19] For example, it has been found that, of the five layers of the cornea, the corneal epithelium is the rate-limiting barrier for most transcorneal permeation, especially water-soluble compounds, whereas the corneal stroma and endothelium are only a significant barrier for small, lipophilic compounds. [20, 21] This is due specifically to the suprabasal layer of the cornea that contains tight junctions between cells as well as a high clauden density limiting the passage of even small molecules into the ocular region. [22] Vitreous clearance of drug Once drugs permeate into the vitreous, they may be cleared from the vitreous before reaching their target posterior ocular tissue. This can occur through two primary routes: (1) anterior route -diffusion in the vitreous to the posterior chamber and outflow in the aqueous humour, or (2) posterior route -diffusion through blood-aqueous barrier (BAB) and blood-retinal barrier (BRB) to systemic circulation. [23] However, intravitreal half-life and clearance from site of intraocular administration has been found to be dependent on a number of factors such as an increased molecular weight, increased dose, as well as a decreased lipophilicity. [24] As a higher intravitreal half-life correlates with a greater therapeutic duration of action, examining these factors can be one method of predicting drug delivery efficacy. For example, there are marked differences in vitreous clearance rate between small lipophilic molecules and larger biologics such as proteins (hours vs days to weeks). [25] Compared to the anterior route, posterior clearance of larger drugs is negligible due to limited permeability of the blood-ocular barriers. [23] Moreover, while small drugs permeate through the ocular barriers more readily than larger drugs, their intravitreal clearance is also much more rapid due to their lower molecular weight allowing rapid vitreous diffusion. [26] Ocular tissue barriers Compared to the barriers discussed above, perhaps the most significant barriers for the systemic delivery of drugs to intraocular tissue are the blood-ocular barriers. The blood-ocular barriers consist of the BAB and BRB. The BAB is comprised of the inner layer of the ciliary epithelium and the iris endothelial layer of the blood vessels and acts to control the diffusion of drug between the blood and aqueous humour. [27] On the other hand, the BRB consists of two major parts: the inner BRB, comprising the retinal endothelial cell layer, and the outer BRB, comprising of the -Consists of mechanisms such as the blinking mechanism, hydrophilic tear film, tear dilution and turnover, the limited conjunctival sac volume of 10 ll, and nasolacrimal drainage. [3] [4] [5] [6] [7] -Collectively, these barriers contribute to why topically instilled drug is typically washed away in 15-40 s. [8, 9] Conjunctiva and nasal absorption of drug -Significant drug absorption into the conjunctiva and nasal cavity results in systemic adverse drug effects. [12] [13] [14] -More importantly, it acts to decrease the drug concentration at the corneal absorptive membrane resulting in low transcorneal penetration. [15] [16] [17] Corneal epithelium barrier -The epithelial layer of the cornea is the rate-limiting barrier for most transcorneal penetration. [19] [20] [21] -Due to the narrow intercellular tight junctions and high claudin density in the superficial layer of the corneal epithelium. [22] Vitreous clearance of drug -Once drugs penetrate into the vitreous body, they can be cleared via two routes: an anterior route and a posterior route. [23] -Compared to the anterior clearance of drugs, the posterior clearance is largely negligible due to the limited permeability of the blood-ocular barriers. [23] Ocular tissue barriers -Consists of the BAB and BRB; together they comprise the most significant barrier to the systemic delivery of drugs. [27] -Limited permeability due to the narrow intercellular tight junctions in the endothelial layer. [28] retinal pigment epithelium (RPE). Together, these two layers of the BRB acts as a significant barrier impeding drug movement from the retina into the blood. This is due to the narrow intercellular tight junctions in the endothelium of the retinal blood vessels and the RPE, especially for hydrophilic or larger molecules. [28] Together, the bloodocular barriers serve a crucial role in regulating the intravitreal microenvironment and are the primary barrier to successful systemic posterior ocular drug delivery.
In addition to the blood-ocular barriers, there are other ocular tissue layers that act as significant, albeit less crucial, barriers to intraocular drug delivery, namely the Bruch's membrane, choroid and sclera. The sclera as a barrier can be considered negligible in comparison with the other tissue layers. For example, compared to the Bruch's membrane and choroid, the sclera is significantly more permeable and thus represents a less significant barrier, especially for lipophilic drugs. [29] Moreover, for a range of compounds, the scleral permeability has also been found to be significantly higher than that of the cornea. [30] The choroid-Bruch's layer, the RPE, choroid and sclera have approximately equal permeability and can be considered equal barriers for lipophilic drugs. However, for hydrophilic compounds and macromolecules, the RPE is up to 10 to 100 times less permeable than for lipophilic drugs. [31] For example, the hydrophilic atenolol is up to eight times less permeable in the RPE than other lipophilic beta-blockers. As such, there is strong evidence that the RPE is the most significant rate-limiting barrier in transscleral drug permeation.
The different types of novel ocular drug delivery systems
As discussed above, the many barriers of the eye can significantly hinder higher therapeutic effectiveness for topical or systemic delivery. However, there has been new research to overcome these barriers which would otherwise be an issue for conventional eye drops. These include formulation changes, direct drug administration to the target tissue and use of drug carriers. To achieve this, the ideal properties of the drug system must first be established to improve the development of effective pharmaceutical systems.
Ideal properties of posterior ocular drug delivery systems
Primarily, there are four characteristics required for posterior ocular drug delivery system which are 1. minimal invasiveness and safety; 2. high target cell specificity to the desired tissue within the eye; 3. the delivery system must display capability of sustained release to reduced frequency of dosing and 4. administration of the drug must be simple, such as allowing self-administration using eye drops as an applicator, or administration from a routine hospital visit. [32, 33] As discussed above, periocular or topical administration when used for posterior ocular delivery faces many challenges. As such, injections to deliver drug to posterior target ocular tissue have been more commonly used.
The chief benefit of intravitreal injection is that it can deliver the drug directly into the back of eye which bypasses many of the defensive features of the eye as previously discussed. [32] Intravitreal injection can also be formulated to provide a sustained release. [32] However, intravitreal injections still face significant limitations; the first involves a risk of endophthalmitis, the second carries a risk of exposing unintended tissues by the drug and lastly, the administration is very invasive. [32, 33] Both periocular and intravitreal administration do not fully conform to the ideal properties discussed above and, thus, novel drug delivery systems are sought that can conform more to the ideal properties. In doing so, a more effective treatment for the posterior segment of eye can be obtained with a better benefit-to-risk ratio for the patient. There are several such DDSs around (Table 2) .
Liposomes
As discussed above, several barriers are present for effective posterior ocular delivery. The use of liposomes may overcome these barriers by limiting the drug delivery to the target tissue site in the eye. [1] Liposomes are closed vesicles that are composed of phospholipid bilayers with watersoluble drugs incorporated into their aqueous phase, whereas lipid-soluble drugs are incorporated into their lipid phase. [1] The use of liposomes in ocular therapeutics displays several advantages over conventional solution-or gel-based eye drops some of which include versatile surface modification chemistry, the ability to modify the drugs rate of release by modifying the number of lipid bilayers and composition of the liposome, and the ability to provide a stimuli-sensitive drug release mechanism. [2] The physicochemical properties of liposomes (size, surface charge, functional chemistry) can be modified by mixing multiple different lipids during the development stage. [2] This, in turn, may produce a liposome that can prolong its residence time at the site of action. [2] Drug delivery to the retina is difficult to achieve through conventional methods such as eye drops due to the presence of the BAB and the inner-outer BRB, which limit drug absorption and drug penetration into the site of action. [1] As a result, large doses of therapeutics are often needed to achieve proper therapeutic effect at the cost of increased side-effects. [1] The use of liposomes can overcome this limitation as it can easily cross these retinal barriers by modifying the composition of the liposome to allow it to penetrate these barriers to access the site of action. [1] This in turn leads to a lower required dosage to achieve the same level of therapeutic effect. [1] Commercial suspensions used in treating ocular conditions such as glaucoma-related pathology has its limitations, some of which include low patient compliance as it produces an uncomfortable feeling and undesirable tear production that can wash away the drug when used. [34] The use of liposomes can overcome the aforementioned limitations by increasing the drug's residence time at the site of action and it also has intraocular pressure-lowering efficacy which may add to the therapeutic effect of treating ocular conditions that require the reduction of intraocular pressure. [34] However, liposomes do present certain limitations, some of which may include increased cost to formulate, scale-up issues, as well as a low reproducibility where it can be difficult to reproduce the same liposome with the same properties as intended. [2] Another limitation also includes the instability of the macromolecules during the production stage of the liposome, where the macromolecule properties may not stay the same throughout the formulation period. [2] Variable size distribution is another limitation as liposomes may not have a constant size after formulation and ensuring all formulated liposomes to have the same size throughout is difficult. [2] Ocular implants Ocular implants are another example of a novel drug delivery method that can be used to administer a drug into the deeper recesses of the eye, especially given its ability to overcome many shortcomings of other drug delivery systems. Ocular implants may come in different forms such as contact lenses, that should be placed near the surface of the eye, or implants, which must be surgically inserted into the eye. [35] Placing ocular implants deep into the sclera prevents the need to surgically enter into the eye which may result in an injury to the lens if an invasive drug delivery such as an injection was used instead. [35] Implants would also decrease the risk of retinal detachment and reduce the risk of developing endophthalmitis. [35] Additionally, using an ocular implant also allows for a sustained release of drug into the eye which can improve patient compliance as the frequency of dose is reduced and thus a reduced risk of toxicity. [35] Ocular implants can also prolong therapeutic duration at the site of action compared to other conventional drug delivery methods such as eye drops. [36] The use of ocular implants can overcome the limitation of topical eye drops where drug wastage is an immediate issue. [36] Ocular implants allow the drug to reside at the site of action without having to deliver a large dose over a long period of time. [37] Despite these many benefits, the intravitreal administration of ocular implants does have major drawbacks, some of which include inconveniencing patients in terms of administration, risk of tissue damage and severe but rare adverse reactions such as endophthalmitis and haemorrhage. [38] In addition, high concentrations of intraocular drug delivery may lead to an increase in intraocular pressure in the eye and it may also induce local systemic adverse effects. [38] In situ gels Like conventional eye drops, in situ gels are another form of topical ocular delivery. In situ gels are a drug delivery system which when administered in a liquid form phase shift into a gel or solid form once reaching the conjunctival cul-de-sac. [39] Despite typically being administered [1, 4] ) 2 Ability to modify the rate of release of drug [1, 4] 3 Ability to provide a stimuli-sensitive drug release mechanism [1, 4] 1 Allow sustained release of drug [35, 36] 2 Prolonged therapeutic duration at site of action [35, 36] 3 Can overcome limitation of eye drops where drug wastage is an issue [35, 36] 1 No blurred vision or irritation with administration [39, 40] 2 Prolonged drug retention at desired tissue in the eye [39, 41] 3 Decreased frequency of dosing [40, 41] 1 Both hydrophilic or lipophilic drugs can be used [32] 2 Increase drug penetration across conjunctival and corneal epithelium [32] 3 Display ability to provide sustained released [32, 46] 4 Decreased frequency of dosing [46] Cons 1 Low reproducibility [4, 48] 2 Instability of the macromolecules during production stage [4, 48] 3 Variable size distribution [4, 48] 4 Expensive [4, 48] 1 May increase intraocular pressure and induce local systemic adverse effects [38] 2 Inconvenient administration for patient [38] 3 Risk of tissue damage if administered incorrectly [38] 1 Lack of cell specificity [41] 2 Requires intravitreal administration due to poor penetration & specificity [40] 3 Expensive [40] 1 Stability issues [47] 2 Control of particle size [47] 3 Control of drug release rate [47] topically like eye drops, the many issues regarding conventional solution-, ointment-or gel-based topical drug delivery such as decreased precorneal drug concentration, lack of patient compliance, and unwanted side-effects such as blurred vision (in ointments) can be overcome from the use of in situ gel. [40] The primary advantage of in situ gels is that, relative to other topical vehicles, it can increase drug precorneal retention in the conjunctival cul-de-sac due to increased viscosity and decreased fluid drainage. Additionally, when administered via implants or with intravitreal injections, the increased viscosity results in an increased retention time in the posterior parts of the eye. Consequently, there is a reduced frequency of administration that can reduce the risks associated with ocular procedures. [39, 41] Despite these benefits, a significant limitation currently for in situ gels is the cost for administration, especially for implants. Additionally, when applied topically, patients may experience temporary blurred vision. [42] Some of the more common polymers used for in situ gels include gellan gum, alginic acid, chitosan and xyloglucan. Gellan gum has recently been used for delivery of the carbonic anhydrase inhibitor brinzolamide (BLZ) for glaucoma-related pathology treatment in rabbits and was found to prolong delivery while being less tissue-reactive compared to non-encapsulated BLZ solutions. [43] Transcorneal delivery of the non-selective beta-adrenergic receptor blocking agent, timolol maleate, was enhanced twofold when administered via chitosan-alginate nanogels in ex vivo rabbit eyes. [44] Nanoparticles Nano-micelle systems are made up of highly stable lipophilic, hydrophilic or amphiphilic molecules and used pharmaceutically to transport drugs to their target site, most often to improve the solubility of the drug. [45] Their primary benefit as a drug carrier for posterior ocular drug delivery is that they are capable of increasing penetration across the conjunctival and corneal epithelium by temporarily altering the tight junctions when administered topically. [45] In addition to their ability to increased transcorneal penetration, their ability to improve the solubility of lipophilic drugs may play an important role in increasing the intravitreal half-life and thus bioavailability of lipophilic drugs like propranolol and metoprolol. [45] Moreover, like in situ gels, they also increase precorneal drug retention time due to their increased viscosity thereby achieving a sustained release formulation leading to a decrease in administration frequency and reduced drug toxicity. [46] Like liposomes, however, nano-carriers share many of the same limitations associated with micelle-based systems including formulation stability, control of particle size, and control of drug release rate and large-scale manufacture of sterile preparations. [47] 
Conclusions
The use of novel drug delivery systems is an alternative in providing therapeutic care in patients suffering from debilitating deep-seated ocular conditions. That is, standard drug delivery systems such as eye drops may not provide the drug's effect to its fullest capacity due to the presence of ocular barriers such as primary physiological barriers, conjunctiva and nasal absorption drug, the corneal epithelium, vitreous clearance of drug, and the ocular tissue barriers. Specifically, these barriers can hinder the drug's ability to reach the intended site of action. As such, the use of novel drug delivery systems taking advantage liposomes, ocular implants, gels or nanoparticles may improve therapeutic outcomes for patients with these debilitating diseases with more research in the upcoming decades.
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